Unlock the potential of GLP-1 therapies! Join experts to explore cutting-edge strategies for managing cardiovascular & ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...
With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...
News Medical on MSN9d
Researchers create an atlas of health associations for GLP-1 receptor agonistsInsights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...
From loss of skin elasticity to hair density, supplements that offer targeted support for GLP-1 users, as well as those that ...
The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3 years. HealthDay News — Glucagon-like peptide 1 receptor ...
A new study reports that GLP-1 medications may provide benefits to cognitive and behavioral health, including lowered addiction risk. Scientists also confirmed that the use of these medications ...
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback